GO:2000467 positive regulation of glycogen (starch) synthase activity: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:2000467 describes any process that activates or increases the frequency, rate or extent of glycogen (starch) synthase activity, the rate-limiting step in glycogen synthesis.
• Glycogen synthase is controlled by phosphorylation: dephosphorylation by protein phosphatases activates the enzyme, while kinases such as GSK-3 phosphorylate and inhibit it.
• In vivo 13C/31P NMR studies in human muscle established that glycogen synthase activity is a key determinant of glycogen synthesis rates after insulin stimulation.
• GSK-3 isoforms (GSK-3α and GSK-3β) are central negative regulators of glycogen synthase; their inhibition relieves phosphorylation-mediated suppression of the enzyme.
• Dysregulation of glycogen synthase regulation is linked to insulin resistance, cancer metabolism, and neurological disorders, making GO:2000467 a target for therapeutic and metabolic research.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal dissection of genes that positively regulate glycogen synthase activity.
Description
Glycogen (starch) synthase is the enzyme that catalyzes the transfer of glucose from UDP-glucose to a growing α-1,4-glucan chain, making it the rate-limiting step in glycogen biosynthesis. The Gene Ontology term GO:2000467, positive regulation of glycogen (starch) synthase activity, captures all biological processes that increase the activity of this enzyme, whether through dephosphorylation, allosteric activation, or changes in protein abundance. Understanding this regulatory node is essential because glycogen synthesis is a major fate of glucose in muscle and liver, and its dysregulation contributes to metabolic disease, cancer, and neurological dysfunction. At the molecular level, glycogen synthase activity is primarily controlled by reversible phosphorylation. Insulin and other anabolic signals promote dephosphorylation and activation of the enzyme, whereas glucagon, epinephrine, and cellular stress activate kinases that phosphorylate and inhibit it. The serine/threonine kinase GSK-3 is a principal negative regulator: it phosphorylates glycogen synthase at multiple C-terminal residues, reducing its activity. Consequently, inhibition of GSK-3 or activation of protein phosphatases constitutes a positive regulatory input for glycogen synthase. Research on GO:2000467 spans metabolic biochemistry, signal transduction, and disease modeling. In vivo magnetic resonance spectroscopy in humans demonstrated that muscle glycogen synthase activity is a strong predictor of glycogen synthesis rates, underscoring its physiological importance. More recent work has linked GSK-3α phosphorylation to sperm motility, GSK-3β to cancer progression and therapy resistance, and GSK-3β to ferroptosis and neuroprotection in Friedreich ataxia models. These findings position positive regulation of glycogen synthase activity as a process with broad biomedical relevance.
positive regulation of glycogen (starch) synthase activity At A Glance
| GO ID | GO:2000467 |
|---|---|
| GO term | positive regulation of glycogen (starch) synthase activity |
| Ontology | biological_process |
| Synonym | positive regulation of glycogen (starch) synthetase activity; positive regulation of UDPG-glycogen synthetase activity; positive regulation of UDP-glucose:glycogen 4-alpha-D-glucosyltransferase activity |
| Major function | Increases the rate of glycogen synthesis by activating glycogen synthase, the rate-limiting enzyme of glycogen biosynthesis. |
| Key upstream regulators | Insulin signaling, protein phosphatases (e.g., PP1), and inhibition of GSK-3 kinases. |
| Physiological context | Muscle and liver glycogen storage; whole-body glucose homeostasis. |
| Disease relevance | Insulin resistance, cancer metabolism, and neurodegenerative conditions. |
| Research methods | Enzyme activity assays, phospho-specific antibodies, CRISPR knockout/knock-in models, and metabolic flux analysis. |
What Is GO:2000467?
GO:2000467 is a biological process term defined as any process that activates or increases the frequency, rate or extent of glycogen (starch) synthase activity. In other words, it encompasses all molecular events that enhance the catalytic activity of the enzyme responsible for adding glucose units to glycogen. This includes dephosphorylation of inhibitory sites on glycogen synthase, relief of kinase-mediated inhibition, and any signaling cascade that ultimately boosts the enzyme's ability to synthesize glycogen.
Why Is positive regulation of glycogen (starch) synthase activity Important in Cell Biology?
Positive regulation of glycogen synthase activity is critical because glycogen synthesis is a major pathway for glucose disposal in response to insulin. Defects in this regulatory process contribute to insulin resistance and type 2 diabetes, while excessive glycogen accumulation can support cancer cell proliferation and survival. Moreover, GSK-3, a key negative regulator of glycogen synthase, is implicated in diverse pathologies including cancer, inflammation, and neurodegeneration, making the pathways that positively regulate glycogen synthase attractive therapeutic targets.
• Controls the rate-limiting step of glycogen synthesis, a major glucose storage pathway in muscle and liver.
• Dysregulation is associated with insulin resistance and type 2 diabetes.
• GSK-3, a negative regulator, is overactive in many cancers and contributes to tumorigenesis and therapy resistance.
• Modulation of glycogen synthase activity affects cancer cell metabolism and survival.
• GSK-3β is involved in ferroptosis and neuroprotective signaling in Friedreich ataxia models.
• Phosphorylation of GSK-3α correlates with sperm motility, linking glycogen synthase regulation to reproductive biology.
• Cholinergic signaling impairs cardiomyocyte cohesion, potentially through GSK-3-dependent mechanisms.
• Wnt signaling, which can inhibit GSK-3, regulates T cell differentiation and memory stem cell formation.
• Glycogen synthase regulation is a downstream node of insulin and AMPK signaling, integrating metabolic cues.
• Targeting positive regulators of glycogen synthase offers opportunities for metabolic and oncological therapeutics.
What Happens During positive regulation of glycogen (starch) synthase activity?
Dephosphorylation of Glycogen Synthase
In simple terms: Removing phosphate groups from glycogen synthase turns the enzyme on.
Glycogen synthase is inhibited by phosphorylation at multiple serine residues near its C-terminus. Positive regulation often involves the action of protein phosphatases, particularly protein phosphatase 1 (PP1), which dephosphorylate these sites and restore catalytic activity. In vivo studies using 13C and 31P NMR in human muscle showed that insulin-stimulated glycogen synthesis is tightly correlated with dephosphorylation and activation of glycogen synthase.
Inhibition of GSK-3 Kinases
In simple terms: Blocking the kinases that add inhibitory phosphates keeps glycogen synthase active.
GSK-3α and GSK-3β are major kinases that phosphorylate and inhibit glycogen synthase. Positive regulation of glycogen synthase activity can occur through inhibition of GSK-3, either by upstream signaling (e.g., insulin via Akt) or by pharmacological inhibitors. For example, in head and neck squamous cell carcinoma, ACTN1 promotes degradation of GSK-3β, which would relieve inhibition of glycogen synthase and potentially enhance glycogen synthesis. Similarly, in Friedreich ataxia models, GSK3β inhibition is part of the NRF2-mediated antioxidant response.
Allosteric Activation by Glucose-6-Phosphate
In simple terms: A metabolite called glucose-6-phosphate binds to glycogen synthase and makes it more active.
Glucose-6-phosphate (G6P) is a potent allosteric activator of glycogen synthase. Binding of G6P promotes a conformational change that increases the enzyme's affinity for UDP-glucose and its catalytic rate, even when the enzyme is partially phosphorylated. This mechanism allows glycogen synthesis to be stimulated when glucose is abundant, linking substrate availability to enzyme activity.
Insulin Signaling Cascade
In simple terms: Insulin triggers a signaling chain that ultimately activates glycogen synthase.
Insulin binding to its receptor activates a cascade involving IRS-1, PI3K, and Akt. Akt phosphorylates and inhibits GSK-3, thereby preventing GSK-3-mediated phosphorylation of glycogen synthase. Additionally, insulin promotes the activation of PP1, which dephosphorylates glycogen synthase. The net result is increased glycogen synthase activity and enhanced glycogen synthesis. This pathway is a classic example of positive regulation of glycogen synthase activity.
Integration with Cellular Stress and AMPK
In simple terms: Cellular energy stress can also influence glycogen synthase activity through AMPK and related pathways.
AMP-activated protein kinase (AMPK) is activated by low energy status and can phosphorylate glycogen synthase directly or indirectly. In Friedreich ataxia models, the LKB1/AMPK pathway is implicated in the regulation of NRF2 and ferroptosis, with GSK3β playing a role. While AMPK generally inhibits glycogen synthesis to conserve energy, its crosstalk with GSK-3 and other regulators can modulate glycogen synthase activity in a context-dependent manner.
Key Genes Involved in GO:2000467 positive regulation of glycogen (starch) synthase activity
The following genes and proteins are central to the positive regulation of glycogen (starch) synthase activity, either as direct regulators or as components of upstream signaling pathways.
| Gene | Major Role | Research Relevance |
|---|---|---|
| GYS1 | Muscle glycogen synthase; catalyzes glycogen synthesis | Target of regulation; mutations cause glycogen storage disease |
| GYS2 | Liver glycogen synthase; catalyzes glycogen synthesis | Regulated by phosphorylation; involved in hepatic glucose homeostasis |
| GSK3A | Glycogen synthase kinase-3 alpha; phosphorylates and inhibits glycogen synthase | Linked to sperm motility and metabolic regulation |
| GSK3B | Glycogen synthase kinase-3 beta; phosphorylates and inhibits glycogen synthase | Implicated in cancer, ferroptosis, and neurodegeneration |
| PPP1R3A | Regulatory subunit of PP1; targets PP1 to glycogen synthase | Mediates dephosphorylation and activation of glycogen synthase |
| PPP1CA | Catalytic subunit of protein phosphatase 1 | Dephosphorylates glycogen synthase, promoting its activity |
| INSR | Insulin receptor; initiates insulin signaling | Upstream activator of glycogen synthase via Akt/GSK-3 inhibition |
| IRS1 | Insulin receptor substrate 1; adaptor in insulin signaling | Mediates insulin-stimulated glycogen synthesis |
| AKT1 | Protein kinase B; phosphorylates and inhibits GSK-3 | Key node linking insulin signaling to glycogen synthase activation |
| PRKAA1 | AMPK catalytic subunit alpha-1; energy sensor | Modulates glycogen synthase activity under metabolic stress |
| STK11 | LKB1; upstream kinase that activates AMPK | Involved in energy stress responses affecting glycogen metabolism |
| ACTN1 | Alpha-actinin-1; promotes GSK-3β degradation | Enhances glycogen synthase activity indirectly in cancer cells |
| MYH9 | Myosin heavy chain 9; interacts with GSK-3β | Facilitates GSK-3β degradation, potentially activating glycogen synthase |
| KEAP1 | Kelch-like ECH-associated protein 1; regulates NRF2 | Links oxidative stress to GSK3β and glycogen synthase regulation |
| NFE2L2 | NRF2; transcription factor in antioxidant response | Modulated by GSK3β; affects cellular redox and metabolism |
| CCR6 | C-C chemokine receptor type 6; marker of B cells | Correlates with GSK-3β activity in Castleman disease |
| WNT3A | Wnt family member 3A; ligand for Wnt signaling | Inhibits GSK-3, potentially activating glycogen synthase |
| CTNNB1 | Beta-catenin; mediator of Wnt signaling | Wnt/β-catenin pathway crosstalks with GSK-3 and glycogen synthase |
How Is positive regulation of glycogen (starch) synthase activity Regulated?
The positive regulation of glycogen synthase activity is itself tightly regulated by multiple signaling pathways. Insulin is the primary hormonal activator: it stimulates Akt, which phosphorylates and inhibits GSK-3α and GSK-3β, thereby preventing inhibitory phosphorylation of glycogen synthase. Insulin also promotes the activation of protein phosphatase 1 (PP1) through regulatory subunits such as PPP1R3A, which dephosphorylates glycogen synthase. Conversely, glucagon and epinephrine activate cAMP-dependent protein kinase (PKA), which phosphorylates and inhibits glycogen synthase, either directly or by activating GSK-3. Cellular energy stress activates AMPK, which can phosphorylate glycogen synthase and reduce its activity, though the interplay with GSK-3 and other regulators is complex. Additionally, Wnt signaling inhibits GSK-3, leading to beta-catenin stabilization and potential cross-talk with glycogen synthase regulation. In cancer, ACTN1 promotes GSK-3β degradation, which may relieve inhibition of glycogen synthase and support anabolic metabolism. In inflammatory conditions such as multicentric Castleman disease, GSK-3β activity in CCR6-positive bone marrow cells correlates with disease activity, suggesting a role for glycogen synthase regulation in immune-metabolic crosstalk.
positive regulation of glycogen (starch) synthase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| GSK3B | Cancer (HNSCC), ferroptosis in Friedreich ataxia, Castleman disease | Knockout or point-mutation in cancer cell lines; overexpression in neuronal models |
| GSK3A | Sperm motility defects | Knockout in spermatocyte cell lines; phospho-mutant knock-in |
| ACTN1 | HNSCC tumorigenesis and cisplatin resistance | Knockout in HNSCC cell lines; overexpression in xenografts |
| GYS1 | Glycogen storage disease, insulin resistance | Knockout in muscle cells; point mutations in GYS1 |
| PPP1R3A | Insulin resistance, glycogen metabolism disorders | Knockout in hepatocytes; knock-in of regulatory subunit mutants |
Cancer Metabolism and Therapy Resistance
Dysregulated glycogen metabolism is increasingly recognized as a hallmark of cancer. In head and neck squamous cell carcinoma, ACTN1 promotes tumorigenesis and cisplatin resistance by enhancing MYH9-dependent degradation of GSK-3β. Since GSK-3β is a negative regulator of glycogen synthase, its degradation would be expected to increase glycogen synthase activity, supporting anabolic growth and survival. This links positive regulation of glycogen synthase activity to chemoresistance and aggressive tumor behavior. Furthermore, GSK-3β is implicated in KSHV-associated cancers, where manipulation of GSK-3 activity affects viral oncogenesis.
Neurodegeneration and Ferroptosis
In Friedreich ataxia models, the ferroptosis pathway in dorsal root ganglia involves LKB1/AMPK, KEAP1, and GSK3β, with impairment of the NRF2 response. GSK3β inhibition is protective in this context, suggesting that positive regulation of glycogen synthase activity (via GSK3β inhibition) may contribute to neuronal survival. This positions glycogen synthase regulation as a potential therapeutic target in neurodegenerative diseases characterized by oxidative stress and iron dysregulation.
Metabolic and Inflammatory Disorders
Insulin resistance is characterized by impaired activation of glycogen synthase in muscle and liver, leading to reduced glycogen synthesis and hyperglycemia. In multicentric Castleman disease-TAFRO, GSK-3β/CCR6-positive bone marrow cells correlate with disease activity, indicating a role for GSK-3β in inflammatory syndromes. Additionally, cholinergic signaling impairs cardiomyocyte cohesion, potentially through GSK-3-dependent mechanisms, linking glycogen synthase regulation to cardiac function. These findings highlight the broad impact of glycogen synthase regulatory pathways on human disease.
From positive regulation of glycogen (starch) synthase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of GSK3B increase glycogen synthase activity? | GSK3B knockout cell line (e.g., HEK293 or cancer cells) |
| Does a specific phosphorylation site on glycogen synthase regulate its activity? | Point-mutation knock-in of GYS1 (e.g., S-to-A or S-to-D) |
| Does ACTN1-mediated GSK-3β degradation affect glycogen synthesis? | ACTN1 overexpression and knockout in HNSCC cells |
| Can a tagged glycogen synthase be used to monitor its localization and interactions? | Knock-in of GFP- or FLAG-tagged GYS1 |
| Does GSK3A phosphorylation status affect sperm motility? | Point-mutation knock-in of GSK3A in spermatocyte models |
| What is the effect of GSK3B inhibition on ferroptosis in Friedreich ataxia? | GSK3B knockout or overexpression in DRG neurons |
How to Study the positive regulation of glycogen (starch) synthase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Enzyme activity assay (UDP-glucose incorporation) | Glycogen synthase catalytic activity | Assessing activation state after genetic or pharmacological perturbation |
| Western blot with phospho-specific antibodies | Phosphorylation status of glycogen synthase and GSK-3 | Determining if a gene regulates inhibitory phosphorylation |
| 13C/31P NMR spectroscopy | In vivo glycogen synthesis rates | Human muscle glycogen metabolism studies |
| CRISPR knockout/activation screen | Genes affecting glycogen synthase activity or glycogen content | Discovery of novel regulators |
| Metabolic flux analysis (13C tracing) | Flux through glycogen synthesis | Quantifying pathway activity in cancer or metabolic cells |
| Co-immunoprecipitation | Protein-protein interactions (e.g., GSK-3 with substrates) | Validating regulatory complexes |
| Immunofluorescence microscopy | Subcellular localization of glycogen synthase | Assessing translocation or aggregation |
| RNA-seq | Transcriptional changes in glycogen metabolism genes | Global response to genetic perturbations |
Enzyme Activity Assays
Glycogen synthase activity is typically measured using radioactive or fluorescent assays that quantify the incorporation of UDP-[14C]glucose into glycogen. These assays can be performed on cell lysates or purified enzyme and are often coupled with phospho-specific antibodies to assess the phosphorylation state of glycogen synthase. In vivo, 13C and 31P NMR spectroscopy can measure glycogen synthesis rates and correlate them with enzyme activity.
Phospho-Proteomics and Western Blotting
Because glycogen synthase activity is regulated by phosphorylation, Western blotting with phospho-specific antibodies against inhibitory sites (e.g., Ser641, Ser645) is widely used. Mass spectrometry-based phosphoproteomics can provide a global view of signaling changes that affect glycogen synthase. These methods are essential for determining whether a candidate gene positively regulates glycogen synthase through dephosphorylation or kinase inhibition.
CRISPR Screening and Functional Genomics
Genome-wide CRISPR knockout or activation screens can identify genes whose loss or gain affects glycogen synthase activity or glycogen content. For example, a screen could use a glycogen-sensitive fluorescent reporter or measure glycogen levels to identify positive regulators. Such screens have been instrumental in uncovering novel components of metabolic pathways.
Metabolic Flux Analysis
Stable isotope tracing with 13C-glucose or 13C-glutamine can quantify flux through glycogen synthesis. Combining this with genetic perturbations (e.g., CRISPR knockout of GSK3B) allows researchers to determine how specific genes affect the rate of glycogen synthesis and its contribution to cellular metabolism.
How CRISPR Can Be Used to Study GO:2000467 positive regulation of glycogen (starch) synthase activity
Knockout
CRISPR knockout of negative regulators such as GSK3B or GSK3A can constitutively activate glycogen synthase, providing a powerful tool to study downstream effects on glycogen storage, cell proliferation, and metabolism. Knockout of positive regulators (e.g., PPP1R3A) would reduce glycogen synthase activity, allowing loss-of-function studies. These models are essential for establishing causality in metabolic and cancer research.
Point Mutation
Point mutations can be introduced into glycogen synthase (GYS1/GYS2) to mimic or prevent phosphorylation at specific serine residues (e.g., S-to-A to block phosphorylation, or S-to-D to mimic it). Such knock-in models allow precise dissection of phosphorylation sites that mediate positive regulation. Similarly, point mutations in GSK3A/GSK3B can alter their kinase activity or substrate specificity.
Knock-in
Knock-in of tagged glycogen synthase (e.g., GFP, FLAG, or HaloTag) enables live-cell imaging, proximity labeling, and proteomic analysis of interacting partners. Knock-in of reporter cassettes under the endogenous GYS1 promoter can also be used to monitor transcriptional regulation. These models are valuable for understanding the spatiotemporal dynamics of glycogen synthase regulation.
Overexpression
Overexpression of positive regulators (e.g., constitutively active Akt, dominant-negative GSK-3) or of glycogen synthase itself can drive glycogen accumulation and reveal metabolic consequences. Conversely, overexpression of negative regulators can suppress glycogen synthesis. These models are useful for studying the impact of glycogen synthase activity on cell growth, survival, and drug resistance.
How EDITGENE Supports positive regulation of glycogen (starch) synthase activity Research
Researchers studying positive regulation of glycogen (starch) synthase activity-related genes often need to determine whether a candidate gene is causally involved in modulating enzyme activity, glycogen storage, or downstream phenotypes. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models, enabling rigorous functional validation of genes in this pathway.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of glycogen (starch) synthase activity research.
Frequently Asked Questions About positive regulation of glycogen (starch) synthase activity
What is GO:2000467?
GO:2000467 is a Gene Ontology biological process term defined as any process that activates or increases the frequency, rate or extent of glycogen (starch) synthase activity, the rate-limiting enzyme of glycogen synthesis.
What genes are involved in positive regulation of glycogen (starch) synthase activity?
Key genes include GYS1 and GYS2 (glycogen synthase isoforms), GSK3A and GSK3B (inhibitory kinases), PPP1R3A and PPP1CA (activating phosphatases), and upstream signaling components such as INSR, IRS1, and AKT1.
How is glycogen synthase activity regulated?
Glycogen synthase is regulated by reversible phosphorylation: kinases such as GSK-3 inhibit it, while protein phosphatases (e.g., PP1) activate it. Allosteric activation by glucose-6-phosphate also increases activity.
What diseases are associated with dysregulated glycogen synthase regulation?
Dysregulation is linked to insulin resistance, type 2 diabetes, cancer (e.g., head and neck squamous cell carcinoma), and neurodegenerative conditions such as Friedreich ataxia.
What is the role of GSK-3 in glycogen synthase regulation?
GSK-3α and GSK-3β phosphorylate glycogen synthase at inhibitory sites, reducing its activity. Inhibition of GSK-3 is a major mechanism for positive regulation of glycogen synthase.
How can I study positive regulation of glycogen synthase activity in the lab?
Common methods include enzyme activity assays, phospho-specific Western blotting, 13C/31P NMR, CRISPR knockout or knock-in models, and metabolic flux analysis.
What CRISPR models are available for studying glycogen synthase regulation?
Knockout of GSK3B or PPP1R3A, point mutations in GYS1 phosphorylation sites, tagged knock-in of GYS1, and overexpression of AKT1 or dominant-negative GSK3B are widely used.
Why is glycogen synthase important for cancer metabolism?
Cancer cells often exhibit increased glycogen synthesis to support anabolic growth. GSK-3β degradation by ACTN1 in HNSCC relieves inhibition of glycogen synthase, promoting tumorigenesis and cisplatin resistance.
What is the connection between GSK-3 and ferroptosis?
In Friedreich ataxia models, GSK3β is involved in the impairment of the NRF2 antioxidant response and ferroptosis in dorsal root ganglia, suggesting that GSK3β inhibition may protect neurons.
How does insulin activate glycogen synthase?
Insulin activates Akt, which phosphorylates and inhibits GSK-3, thereby preventing inhibitory phosphorylation of glycogen synthase. Insulin also promotes PP1-mediated dephosphorylation of glycogen synthase.
Conclusion
GO:2000467, positive regulation of glycogen (starch) synthase activity, represents a critical regulatory node in glucose metabolism with far-reaching implications for metabolic disease, cancer, and neurodegeneration. The interplay between kinases such as GSK-3 and phosphatases such as PP1 determines the activation state of glycogen synthase, and this balance is frequently perturbed in human pathologies. Understanding the molecular mechanisms and identifying novel regulators of this process are essential for developing targeted therapies. CRISPR-based models, including knockout, point-mutation, knock-in, and overexpression cell lines, provide powerful tools to dissect the causal roles of specific genes in glycogen synthase regulation. Combined with advanced methods such as phosphoproteomics, metabolic flux analysis, and CRISPR screening, these approaches will continue to illuminate the pathways that control glycogen synthesis and their contribution to health and disease.
References
- 1. Gattinoni L et al.. 2009. Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells.. Nat Med 15(7):808-13 PMID: 19525962
- 2. Park SH et al.. 2024. Regulation of Phosphorylation of Glycogen Synthase Kinase 3α and the Correlation with Sperm Motility in Human.. World J Mens Health 42(2):373-383 PMID: 37635337
- 3. Cui L et al.. 2023. ACTN1 promotes HNSCC tumorigenesis and cisplatin resistance by enhancing MYH9-dependent degradation of GSK-3β and integrin β1-mediated phosphorylation of FAK.. J Exp Clin Cancer Res 42(1):335 PMID: 38057867
- 4. Shulman RG et al.. 1995. In vivo regulation of muscle glycogen synthase and the control of glycogen synthesis.. Proc Natl Acad Sci U S A 92(19):8535-42 PMID: 7567971
- 5. Sanz-Alcázar A et al.. 2024. Deciphering the ferroptosis pathways in dorsal root ganglia of Friedreich ataxia models. The role of LKB1/AMPK, KEAP1, and GSK3β in the impairment of the NRF2 response.. Redox Biol 76:103339 PMID: 39243573
- 6. Abe N et al.. 2022. Glycogen synthase kinase 3β/CCR6-positive bone marrow cells correlate with disease activity in multicentric Castleman disease-TAFRO.. Br J Haematol 196(5):1194-1204 PMID: 34873687
- 7. Fujimuro M et al.. 2004. Manipulation of glycogen-synthase kinase-3 activity in KSHV-associated cancers.. J Mol Med (Berl) 82(4):223-31 PMID: 14991150
- 8. Yeruva S et al.. 2022. Cholinergic signaling impairs cardiomyocyte cohesion.. Acta Physiol (Oxf) 236(3):e13881 PMID: 36039679
